In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
TRENDS
Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
To read the full story
Related Article
- Chugai Ups Core EPS CAGR Target to “Around 30%”: 3-Year Biz Plan
January 31, 2020
- Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
- Chugai Plays It Safe with New 3-Year Plan on Consecutive Re-Pricing, Eyes 7-9% Annual EPS Growth
February 1, 2019
TRENDS
- Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
- Top 10 PHARMA JAPAN Articles in 2022
December 28, 2022
- 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
- Top 10 PHARMA JAPAN Articles in 2021
December 28, 2021
- Top 10 PHARMA JAPAN Articles in 2020
December 28, 2020
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…